---
title: "Kennametal Inc. Stock 12‑Month Price Target Cut to $36.21, Implies 2% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293022006.md"
description: "Analysts have lowered Kennametal Inc.'s 12-month average price target from $36.93 to $36.21, implying a 2% upside based on the July 16 closing price. Forecasts range from $31 to $47.50. The consensus rating remains 'Sell' among eight covering analysts, with no buys, five holds, and three sells."
datetime: "2026-07-17T10:20:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293022006.md)
  - [en](https://longbridge.com/en/news/293022006.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293022006.md)
generator: "portal-rs"
---

# Kennametal Inc. Stock 12‑Month Price Target Cut to $36.21, Implies 2% Upside

-   According to estimates from 7 analysts, Kennametal Inc. stock's average price target has fallen from $36.93 to $36.21, with forecasts ranging from $31 to $47.5 per share
-   Based on the Jul. 16 closing price, the updated target implies approximately 2% potential upside
-   Consensus rating remains at “Sell” across 8 covering analysts, with 0 Buys, 5 Holds and 3 Sells

Explore more price target data and ratings for Kennametal Inc. on the , and track all previous and future analyst recommendations for Kennametal Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [KMT.US](https://longbridge.com/en/quote/KMT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Kennametal VP Michelle R. Keating disposes of 20,000 common shares for $610,720](https://longbridge.com/en/news/298356427.md)
- [Kennametal director Richard J. Harshman acquires $151,050 of common shares](https://longbridge.com/en/news/298358083.md)
- [Latigo Biotherapeutics, Inc.'s Quiet Period Will End  on September 16th (NASDAQ:LTGO)](https://longbridge.com/en/news/298403254.md)
- [Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In?](https://longbridge.com/en/news/298137481.md)
- [Curtiss-Wright Corporation (NYSE:CW) Receives Average Recommendation of "Hold" from Analysts](https://longbridge.com/en/news/298012562.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**